Macy’s Stock Forecast: Macy’s Putting Up Fight Against Online Retail Behemoths

This article was written by Julia Masch, a Financial Analyst at I Know First.

“Macy’s, Inc.’s results for the first quarter of 2018 reflect continuing momentum in the business. We exceeded our expectations and saw strong performance across all three brands—Macy’s, Bloomingdale’s, and Bluemercury—as well as across all geographic regions and families of business.”

-Jeff Gennette, chairman and CEO of Macy’s, Inc

(Source: Wikimedia Commons)

Summary:

  • Stock price surge on strong Q1 report
  • New initiatives to compete with Amazon
  • Implementation of Virtual and Augmented Reality
  • I Know First Current Bullish Forecast for Macy’s Stock

Macy’s, Inc., (NYSE: M) operates about 700 department stores under the Macy’s and Bloomingdale’s as well as websites and mobile applications which sell a variety of merchandise such as men’s and women’s apparel and accessories, cosmetics, home goods, etc.. 

Read More

Winning Stock Forecast: Nektar Therapeutics (NASDAQ: NKTR) Up 340.47% In 1-Year As Forecasted Amid Its Stock Volatility

Winning Stock Forecast: Nektar Therapeutics (NASDAQ: NKTR) Up 340.47% In 1-Year As Forecasted Amid Its Stock Volatility

[Source: Live Trading News, May 23, 2018]

“Already, this year to-date, we have achieved multiple successes with our pipeline of Nektar invented medicines across three therapeutic areas, immuno-oncology, immunology and pain. In the area of chronic pain, we will submit the NDA for NKTR-181 to the FDA this month”

— Howard Robin – President and CEO of Nektar Therapeutics

Summary

  • Over the past year  NKTR went up 340.47%
  • They are one of the most robust growers investors more so during the past 12 months – due to many catalysts powering the firm.
  • Nektar recently commenced the phase 1B study of NKTR-358 for systemic lupus erythematosus.
  • If the mentioned drug can post robust clinical outcomes as prognosticated, it can cut into the $45.5B autoimmune diseases market to deliver significantly more upsides for Nektar.

Over the past year, from May 21 2017 through May 21 2018, NKTR produced a whopping 340.47% return to investors. Nektar Therapeutics is one of the most robust growers investors have encountered in all years of analytical research, especially during the past 12 months: this is due to many catalysts powering the firm. One, the company obtained the $1.85 billion collaborative deal with Bristol-Myers Squibb on February 14, 2018 for the investigation of NKTR-214 in 20 different cancer diagnoses. Approximately two months afterwards (on April 12), the company announced the dosing of the first patient in the REVEAL trial that created substantial value to their investing thesis. Nevertheless, all recent developments are minuscule compared to what will come. In this article, we’ll clarify the latest catalysts that gave Nektar substantial upside in the long haul, and will continue to do so in the coming months.

Read More

Winning Stock Forecast: Whiting Petroleum Corporation (NYSE: WLL) Returns up to 19.14% in 14 days as forecasted

Whiting Petroleum Corporation engages in the acquisition, exploration, development, and production of crude oil, natural gas liquids, and natural gas primarily in the Rocky Mountains region of the United States. The company sells its oil and gas production to end users, marketers, and other purchasers. As of December 31, 2017, it had interests in 1,980 net productive wells on approximately 490,000 net developed acres, as well as total estimated proved reserves of 617.6 million barrels of oil equivalent. The company was founded in 1980 and is headquartered in Denver, Colorado.

Over the 14 days after I Know First issued its bullish forecast for WLL on May 7, 2018, Whiting Petroleum Corporation’s stock price jumped from $46.54 to $53.39 per share, outperforming the market by about 14%. The company’s Q1 results of 2018 contributed to the growth, released with the following highlights:

Read More

Press Release: New Partnership with Japanese Firm Will Now Represent I Know First in Japan

Press Release: New Partnership with Japanese Firm Will Now Represent I Know First in Japan

Press Release: Tel Aviv, Israel, May 23th, 2018 – Location: Nihonbashi Honcho-ku, Tokyo

As of this week, I Know First has contracted a new partnership with Japanese Firm, IST which will now represent I Know First as a Fintech firm in Japan. I Know First is particularly invested and involved in the Japanese stock exchange, as detailed and described in the following article –click here to view. This new partner firm will represent I Know First in Japan so that they may get more exposure to the Japanese population and appease investors there. After all, I Know First serves the Japanese exchanges and provides daily AI Machine-Learning algorithms for Japanese stocks as well. According to the IST website, IST Co., Ltd. develops, services and sells FinTech related software, algorithms and systems including ” =&0=&as of recently. 

As of December 28th 2017, I Know First finished the implementation and the training period of its AI-based ranking and forecasting model for the main equities listed on the Tokyo Stock Exchange. On this date, the first Japanese stock forecast was published for the subscribed investors in the local Japanese market, as the timing of the data feed and the forecast generation was adjusted to the respective time zone. Since then, the predictions generated returns greatly surpassing that of the Nikkei. I Know First’s AI-based forecasting system covers 1225 of the most liquid stocks listed on the Tokyo Stock Exchange, including 219 of the Nikkei 225 index constituents.

Read More

Winning KERX Stock Forecast: Keryx Biopharmaceuticals Continues To Save Its Patients And Surges With 19.55% In 7 Days

“Revenue growth in the first quarter of 2018, as compared to the first quarter of 2017, was driven by an increase in Auryxia prescription and tablet demand, partially offset, by a reduction in the net price realized per tablet due to an increase in our gross-to-net adjustment”

– Scott Holmes, Senior Vice President and CFO of Keryx Biopharmaceuticals

[Image Source: Glassdoor]

Over the 7 days period from May 9th to May 16th, 2018 KERX stock price saw significant price jump of more than 19%. The overall KERX stock performance indicators for the last quarter suggest that this may be the consequence of the company’s results achieved in 1Q 2018. Based on the press release on May 10, 2018 the following highlights are important to analyse:

Read More

Market Predictions Based on Big Data: Returns up to 340.47% in 1 Year

Best Share To Buy Package Name: High Volume Stocks
Recommended Positions: Long
Forecast Length: 1 Year (05/21/2017 - 05/21/2018)
I Know First Average: 90.56%

Read The Full Forecast

Market Predictions

Best Energy Stocks Based on Algorithmic Trading: Returns up to 202.73% in 3 Months

Package Name: Energy Stocks
Recommended Positions: Long
Forecast Length: 3 Months (02/21/2018 - 05/21/2018)
I Know First Average: 21.94%

Read The Full Forecast

Best Energy Stocks